Next steps with 1% tenofovir microbicide gel
24 November 2010
After nearly 20 years of research, the results of the CAPRISA 004 trial provided the first evidence that the use of a vaginal microbicide could provide a safe and effective way to prevent HIV infection in women.
Following results from a South African study (CAPRISA 004) showing that a vaginal microbicide gel containing the antiretroviral drug tenofovir was 39% effective in reducing a woman’s risk of becoming infected with HIV during sex, WHO and UNAIDS convened a meeting in August 2010, just a month following the announcement, to review the implications of the CAPRISA 004 results and determine the appropriate next steps.
The meeting participants agreed on the below priority actions for follow-up:
- Additional safety studies;
- Effectiveness trial in South Africa to confirm the CAPRISA 004 BAT 24 dosing regimen;
- Effectiveness and safety trial of simplified dosing and HIV testing schedules;
- Implementation study in South Africa; and,
- Treatment outcome and resistance study.
Related feature storiesWHO report shows progress on HIV-associated TB but pace needs to be faster
23 October 2014UNAIDS International Goodwill Ambassador Victoria Beckham reaches out to young women and girls
15 October 2014President of South Africa and UNAIDS Executive Director discuss HIV and the Ebola outbreak
05 September 2014
- Next Steps with 1% Tenofovir Gel (pdf, 480 Kb.) (November 2010)
- Executive Summary (pdf, 128 Kb.) (November 2010)